Slovakia Unable to Call Russian Vaccine Safe Due to Lack of Data
(Bloomberg) -- Slovakia's medicines regulator is unable to recommend the use of a Russian coronavirus vaccine because it doesn't have enough information to evaluate it, a senior state official said, a week after a spat over the shots brought down the prime minister.
“Because of our inability to obtain sufficient data from the producer of Sputnik V, there is no other choice but to again request reliable and verifiable evidence that the vaccine is safe and effective,” Janka Bitto Ciganikova, the head of parliament's health-care committee, said in a statement.
Slovak newspaper DennikN cited a report from the local drug regulator as saying that Sputnik vaccines delivered to the country had different parameters than those reviewed in a study published in The Lancet, which showed it to be highly effective against Covid-19. The watchdog declined to comment on the peer-reviewed study.
Sputnik's developer rejected DennikN's report. “Unfortunately, we also expect additional fake news and provocations from enemies of Sputnik V in Slovakia who try to undermine the vaccine,” it said on the vaccine's official Twitter account.
The Slovak regulator is still conducting tests, but it said that it hasn't been able to come to a conclusion about the risks and benefits of Sputnik V because of the “lack of a large amount of data from the producer, the inconsistency of the drug forms and the inability to compare batches used in various studies and countries.”
The nation of 5.5 million agreed to buy 2 million Sputnik V shots and received about 200,000 last month, but the purchase sparked a political crisis when junior coalition parties said the deal had been agreed behind their backs. The turmoil ended when then Premier Igor Matovic swapped jobs with the finance minister.
Read more: Vaccine Dispute Ousts Slovak Premier as EU Virus Woes Deepen
Foreign Minister Ivan Korcok has called Sputnik “a tool in a hybrid war” as the country's right-of-center parties expressed concerns its purchase may undermine the European Union and NATO member's foreign-policy direction.
So far, neighboring Hungary has been the only EU country to approve and use Sputnik, though several other governments have expressed interest, and the vaccine is being reviewed by the bloc's drug regulator. The Financial Times reported on Wednesday that the European watchdog will launch an investigation next week into the ethical and scientific standards of Sputnik V clinical trials.
©2021 Bloomberg L.P.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.